Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

NICE should reconsider osteoporosis guidance say 40 experts

By Nigel Praities

NICE must reconsider its ‘unworkable' guidance on osteoporosis and allow greater access to alternative treatments to alendronate, says a letter signed by 40 clinical leaders published in The Times.

The letter comes as NICE holds a second appeal hearing on technology appraisals for the primary and secondary prevention of osteoporosis that were begun six years ago and are still not completed.

The signatories say the appraisals are ‘unethical and short-sighted', restricting access to alendronate and other alternatives to prevent fractures until their osteoporosis has become significantly worse.

‘Over the next few weeks NICE will have the opportunity to put this right. We hope that this time around the opportunity is grasped with both hands so that we can then all pursue a more enlightened approach to the management of osteoporosis,' the letter reads.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say